ArticleEuropean journal of medical research2026
Potential oncogene VPS72 in hepatocellular carcinoma: prognostic and immune infiltration implications.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics identification of an antibody dependent cellular phagocytosis related signature for hepatocellular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundVPS72, primarily located in the nucleus, may play a role in hepatocellular carcinoma (HCC) progression. More research is required to assess if VPS72 mRNA or protein levels, along with clinical parameters, can diagnose or predict HCC and affect its progression through immune cell infiltration regulation.
methodsThis study explored VPS72 mRNA and protein levels in HCC using bioinformatics and clinical samples, examining their relationship with clinical factors and immune cell infiltration.
resultsVPS72 levels were higher in HCC patients and linked to histologic grade, clinical stage, and T stage. Elevated mRNA and protein levels of VPS72 were associated with preoperative alpha-fetoprotein (AFP) levels and tumor thrombus in HBV-related HCC, while genetic changes increasing VPS72 mRNA correlated with lower overall survival (OS). VPS72 promoter hypomethylation was observed in HCC, and Cox regression showed VPS72 as an independent prognostic factor. A nomogram links Vps72 levels to HCC risk, and the ROC curve demonstrates Vps72's diagnostic potential. GSEA indicates Vps72 overexpression enhances purine and pyrimidine metabolism and cell cycle pathways. HCC tissues have more M0 macrophages, associated with poor prognosis, and high Vps72 expression is linked to increased M0 macrophage infiltration and decreased CD4
conclusionsVPS72 may function as an oncogene, worsening OS by reducing tumor-fighting CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.